Forced Degradation Behaviour with a Developed and Validated RP-UPLC Method for Estimation Lamivudine and Dolutegravir in Combined Pharmaceutical Dosage Form
Journal of Pharmaceutical Research International,
Page 39-46
DOI:
10.9734/jpri/2022/v34i37B36206
Abstract
A simple, fast, precise, specific, and accurate reversed phase Ultra Performance Liquid Chromatographic (UPLC) method was developed and validated for the forced degradation studies of the Lamivudine and Dolutegravir in tablet dosage form. Chromatogram was run HSS C18 (2.6 x 50mm, 1.6µm). Mobile phases containing 70% 0.01N disodium hydrogen phosphate: 30% Methanol). The elution of analytes was achieved with a flow rate at 0.3 mL/min. Potassium dihydrogen phosphate was used as a buffer in this experiment. Temperature was maintained at 30°C. Optimized wavelength selected at 260nm. The detector response was linear in the concentration range of 25-150μg/mL respectively. Retention time of Lamivudine and Dolutegravir were found to be 1.408min and 1.739min. %RSD of the Lamivudine and Dolutegravir were and found to be 0.8 and 0.8. The % recovery was obtained as 100.39% and 100.37% for Lamivudine and Dolutegravir. LOD, LOQ values obtained from regression equations of Lamivudine and Dolutegravir were 0.41, 1.25 and 0.09, 0.26. Regression equation of Lamivudine was y = 24270x + 12218 and for Dolutegravir was y = 34783x + 1060. Since retention times and run times were reduced, the method established was easy and premium and it could be used in periodic quality control tests in industries.
Keywords:
- Lamivudine
- dolutegravir
- RP-UPLC
- forced degradation
How to Cite
References
A to Z drug facts. Ed. 7; Wolters Kluwer Health Inc. 2006;7(2):1313-1387.
Tripathi KD, Essentials of Medical Pharmacology. JP Medical Ltd: 2006;1(6): 565-568.
ICH Guidelines: Text on validation of analytical procedures. In proceedings of International Conference on Harmonization.1994;1-5.
Somshankar D, Mahesh D. Simultaneous estimation of Lamivudine, Abacavir and Dolutegravir by UPLC method. International Journal of Applied pharmaceutics. 2018;1(10):44-49.
Devanna N, Benzil D, Ramachandraiah C. Development and validation for the simultaneous estimation of Dolutegravir and Lamivudine in drug product by RP-HPLC. International journal of research in pharmaceutical and nano sciences. 2017; 6(4):173 -180.
Michael ES, UPLC: An Introduction and Review Waters Corporation, Milford, Massachusetts, USA. Journal of Liquid Chromatography & Related Technologies. 2005;28(3):1253–1263.
Lars Y, Honore HS. On-line turbulent-flow chromatography high-performance liquid chromatography mass spectrometry for fast sample preparation and quantitation. Journal of Chromatography. 2003;1(10): 59–67.
Goodwin L, White SA, Spooner N. Evaluation of ultra-performance liquid chromatography in the bioanalysis of small molecule drug candidates in plasma. Journal of Chromatography Science. 2007; 45(6):298–304.
Sowjanya B, Development and validation for the simultaneous estimation of Lamivudine and Dolutegravir in drug product by RP-HPLC, indo American journal of pharmaceutical research. 2018; 12(3):225-229.
Dhanve A, Rao JR, Dhale C. Development and Validation of Stability Indicating HPTLC Method For Simultaneous Estimation of Lamivudine and Dolutegravir Sodium in Bulk and Pharmaceutical Dosage Formulation. International Journal of Pharmaceutical Sciences and Research. 2018;9(11):4701-8.
Kalpana N, Shanmukha KV, Ramachandran D. Development and Validation for the Simultaneous Estimation of Lamivudine, Tenofovir Disproxil and Dolutegravir in Drug Product by RP-HPLC. Journal of Pharmaceutical Science and Research. 2017;9(9):1505-10.
-
Abstract View: 52 times
PDF Download: 20 times
